Sucralose for Crohn's Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This study will focus on the commonly used non-nutritive sweetener (NNS) sucralose (2 sachets/day resulting in daily dose: sucralose 2.5mg/kg) and its role in changing the gut microbiota in humans with Inflammatory Bowel Disease (IBD), compared to healthy non-IBD individuals. We will focus on studying IBD patients affected with Crohn's Disease (CD) as a proof of principle that could be tested later in other IBD subtypes (ulcerative colitis or others specific surgical conditions).
Who Is on the Research Team?
Fabio Cominelli, MD, PhD
Principal Investigator
Case Western Reserve University
Abigal Raffner, PhD, RD
Principal Investigator
Case Western Reserve University
Are You a Good Fit for This Trial?
This trial is for adults diagnosed with Crohn's Disease, a type of inflammatory bowel disease (IBD), as well as healthy people without IBD. Participants should not have other types of IBD or recent surgeries related to the condition.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Sucralose
Trial Overview
The study tests whether taking sucralose, an artificial sweetener (2 sachets per day), changes gut bacteria in people with Crohn's Disease compared to healthy individuals. The design compares these two groups over time.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Healthy control participants will consume the artificial sweetener sucralose
Crohn's participants will consume the artificial sweetener sucralose
Find a Clinic Near You
Who Is Running the Clinical Trial?
Case Western Reserve University
Lead Sponsor
Crohn's and Colitis Foundation
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.